160 related articles for article (PubMed ID: 17177032)
1. [Systemic treatment of liver and biliary tumors].
Malek NP; Greten T; Kubicka S
Internist (Berl); 2007 Jan; 48(1):46-9. PubMed ID: 17177032
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
3. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
5. Systemic and targeted therapy for biliary tract tumors and primary liver tumors.
Thomas MB
Surg Oncol Clin N Am; 2014 Apr; 23(2):369-81. PubMed ID: 24560115
[TBL] [Abstract][Full Text] [Related]
6. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Guion-Dusserre JF; Lorgis V; Vincent J; Bengrine L; Ghiringhelli F
World J Gastroenterol; 2015 Feb; 21(7):2096-101. PubMed ID: 25717243
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
Harris WP; Wong KM; Saha S; Dika IE; Abou-Alfa GK
Semin Oncol; 2018 Jun; 45(3):116-123. PubMed ID: 30348531
[TBL] [Abstract][Full Text] [Related]
9. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
Sadeghi S; Bejjani A; Finn RS
Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
[TBL] [Abstract][Full Text] [Related]
10. Time to move to targeted drugs in biliary tract cancer?
Louvet C; Tournigand C
Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
[No Abstract] [Full Text] [Related]
11. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
14. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
Gadaleta-Caldarola G; Rizzo A; Dadduzio V; Lombardi L; Gadaleta-Caldarola A; Infusino S; Cusmai A; Citrigno C; Palmiotti G
Curr Oncol; 2022 Oct; 29(10):7925-7931. PubMed ID: 36290903
[TBL] [Abstract][Full Text] [Related]
15. [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Shimizu J; Hayashi S; Dono K; Yasumoto T; Zenitani M; Munakata K; Watanabe N; Takamoto K; Kagawa Y; Hata T; Kawanishi K; Ikeda K; Fujita J; Akagi K; Kitada M; Shimano T
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2380-2. PubMed ID: 20037429
[TBL] [Abstract][Full Text] [Related]
16. Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
Lin ZY; Chuang WL; Chuang YH; Yu ML; Hsieh MY; Wang LY; Tsai JF
J Gastroenterol Hepatol; 2006 Feb; 21(2):398-405. PubMed ID: 16509865
[TBL] [Abstract][Full Text] [Related]
17. [Medical management of cholangiocarcinomas in 2015].
Marret G; Neuzillet C; Rousseau B; Tournigand C
Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
[TBL] [Abstract][Full Text] [Related]
18. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W; Laurent-Puig P; Ziol M; Ganne-Carrié N; Nahon P; Ait-Omar A; Seror O; Sidali S; Campani C; Blanc P; Lermine A; Marisa L; Zucman-Rossi J; Nault JC
J Hepatol; 2023 Dec; 79(6):1450-1458. PubMed ID: 37647991
[TBL] [Abstract][Full Text] [Related]
19. [Systemic treatment of biliary tract cancer].
Jensen LH; Larsen O
Ugeskr Laeger; 2013 Oct; 175(42):2478-81. PubMed ID: 24629114
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for biliary tract cancers.
Faris JE; Zhu AX
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
